Ookawa K, Sakamoto M, Hirohashi S, Yoshida Y, Sugimura T, Terada M, Yokota J
National Cancer Center Research Institute, Tokyo, Japan.
Int J Cancer. 1993 Feb 1;53(3):382-7. doi: 10.1002/ijc.2910530307.
To identify genetic alterations associated with acquisition of metastatic ability in colorectal carcinoma, 31 liver metastases and 40 primary tumors of colorectal carcinoma from 55 patients were analyzed for loss of chromosomal heterozygosity using 46 polymorphic DNA markers covering 15 chromosomes. Loss of heterozygosity (LOH) and/or rearrangement at the TP53 and DCC loci were detected in all liver metastases (10 of 10 at TP53 and 19 of 19 at DCC), and were observed in 59% (10 of 17) at TP53 and 75% (18 of 24) at DCC respectively in the primary tumors. Furthermore, the incidence of LOH on chromosomes 13q and 14q was higher than that on other chromosomes in liver metastasis, and it was higher in liver metastases than in primary tumors (20/30 vs. 18/39, p = 0.072 on chromosome 13q and 21/31 vs. 16/40, p = 0.018 on chromosome 14q). In 4 cases, LOH or rearrangement at loci on chromosomes 13q, 14q and 18q not detected in primary tumors was observed in liver metastases from the same patients. These results suggest that concordant p53 and DCC alterations and inactivation of several other tumor-suppressor genes, especially those on chromosomes 13q and 14q, play important roles in the acquisition of metastatic potential of colorectal carcinoma.
为了鉴定与结直肠癌转移能力获得相关的基因改变,我们使用覆盖15条染色体的46个多态性DNA标记,对55例患者的31个结直肠癌肝转移灶和40个原发性肿瘤进行了染色体杂合性缺失分析。在所有肝转移灶中均检测到TP53和DCC基因座的杂合性缺失(LOH)和/或重排(TP53位点10/10,DCC位点19/19),原发性肿瘤中TP53和DCC位点的杂合性缺失分别为59%(17例中的10例)和75%(24例中的18例)。此外,肝转移灶中13q和14q染色体上的LOH发生率高于其他染色体,且肝转移灶中的发生率高于原发性肿瘤(13q染色体上为20/30 vs. 18/39,p = 0.072;14q染色体上为21/31 vs. 16/40,p = 0.018)。在4例患者中,在来自同一患者的肝转移灶中观察到原发性肿瘤中未检测到的13q、14q和18q染色体位点的LOH或重排。这些结果表明,p53和DCC基因的一致性改变以及其他几个肿瘤抑制基因的失活,尤其是13q和14q染色体上的那些基因,在结直肠癌转移潜能的获得中起重要作用。